An Oxford doctor's call for broader menopause care puts daily wellbeing alongside libido, with context on HRT evidence and regular reviews.
In a report published on November 1, 2026, the Oxford Mail described lifestyle medicine specialist Ellen Fallows's call for menopause care that addresses wider health and wellbeing. Her argument puts psychological wellbeing and daily functioning alongside individual symptoms, rather than allowing a narrow symptom list to define the conversation.
The report names hot flushes, irregular periods and reduced libido as common symptoms. But Fallows said many women she speaks to are more concerned with how hormonal changes affect everyday life than with libido alone.
For sexual wellbeing, the distinction matters. A broader approach need not push desire out of the conversation. It makes room for desire without assuming that it is every woman's main concern or the best measure of whether care is helping.
The Oxford Mail article reports a clinician's views rather than a research paper or a clinical guideline. Its scope includes women's experiences of perimenopause and menopause, the priorities they bring to care and the role of hormone replacement therapy. That treatment is usually called HRT.
Fallows is described as due to join Welbeck Oxford, a private specialist healthcare centre, in 2027. That professional affiliation is relevant context. Her comments represent a named clinician's perspective rather than an independent assessment of a treatment or service.
The report provides no sample size, survey methods or observation period for her account of women's priorities. Her observations describe the women she speaks to. They do not establish how priorities are distributed across the wider population experiencing menopause.
The useful question raised by this report is therefore about the scope of care: whose concerns set the agenda, and how much room is there for experiences that do not fit a short symptom list?
“Most women I speak to say that addressing a dwindling libido is not their top priority,” Fallows told the Oxford Mail. She said women want to “feel more like themselves again, both mentally and physically.”
Her emphasis was on psychological effects as well as physical symptoms. She argued for personalised care because women's experiences differ, making a one-size-fits-all approach ineffective in her view.
That is not an argument that sexual desire is unimportant. It is an argument against assigning the same priority to it for everyone. Someone concerned about intimacy and someone more troubled by how they feel throughout the day may arrive with different goals, even when both are seeking menopause support.
The distinction also separates the presence of a symptom from its importance to the person experiencing it. A symptom list may establish what is happening. A conversation about priorities establishes which changes the person most wants help understanding or addressing.
Fallows also discussed HRT as one possible part of care. She said it may offer some women benefits beyond symptom relief, including support for bone density, heart health and muscle strength. Those statements were presented as her clinical views.
On treatment duration, she stressed regular HRT reviews and said there is no set age at which treatment must stop. She also urged women to consider breast-cancer risk within the context of their overall health and medical history, rather than viewing that risk in isolation.
Taken together, her comments describe an approach centred on individual experience and ongoing discussion. They do not reduce menopause care to restoring libido or to making a single decision about hormones.
The HRT comments need a different level of scrutiny from the report's message about listening to patients. A call to consider wider wellbeing does not establish a particular treatment's long-term effects.
The National Institute for Health and Care Research describes research into cardiovascular outcomes associated with HRT. It includes a study using anonymised GP records to compare women who used HRT with similar women who did not. That is an observational comparison, not evidence from randomly assigning treatment.
Such comparisons can help researchers examine patterns. They do not automatically establish that treatment caused a difference in outcomes. The research packet does not provide results from that study, so it should not be treated as confirmation of Fallows's comments about heart health.
In particular, the Oxford Mail report does not establish that HRT prevents heart disease. Nor does the absence of a fixed stopping age establish that continued treatment is suitable for everyone indefinitely.
These boundaries matter because the report brings together two different subjects: what women want from care and what a treatment may offer. Listening more broadly is not the same as recommending hormones more broadly.
The emphasis on individual circumstances fits existing patient-facing information. The Royal College of Nursing's HRT explainer says suitability depends on personal and family medical history, along with other individual risk factors. It emphasises tailoring treatment to the person.
That guidance gives practical meaning to personalised care. A discussion about what matters to someone and a clinical assessment of treatment suitability belong together. A person's priorities help define the discussion, while medical history and risk remain part of the decision.
Fallows's emphasis on regular reviews also aligns with The Menopause Charity's guidance. The charity advises that people starting HRT should usually have a review after three months and then yearly while using it. This supplies practical context that the Oxford Mail article itself does not specify.
The charity also suggests keeping notes about symptoms and how someone feels. Those notes can support a review by giving the conversation a clearer account of what has changed. This is a preparation tool, not a test that determines which treatment someone needs.
Its guidance also recognises a place for another appointment to discuss symptoms and support when someone is not using HRT. Follow-up is therefore not only a matter of reviewing a prescription. It can also provide space to reconsider concerns and the support available.
The agreement across these sources is about individual assessment and continuing discussion. The news report adds a clinician's argument for a wider agenda. The existing guidance provides a more concrete framework for reviewing care over time.
For readers, the practical significance is not that libido should move down everyone's list. It is that the list should belong to the person seeking care. Mood and sleep can be discussed alongside physical symptoms, confidence and intimacy when those concerns are part of someone's experience.
Putting those experiences into words does not require deciding in advance whether their cause is hormonal, physical or psychological. The report supports bringing the concerns into the conversation. Questions about causes and treatment choices belong with a qualified healthcare professional who can consider the person's circumstances.
The Menopause Charity's suggestion to keep notes offers a straightforward way to prepare. A record can describe symptoms and how someone feels without attempting to diagnose them. The emphasis is on making personal priorities clearer before a menopause care discussion, rather than arriving with a predetermined treatment request.
Questions grounded in the report and accompanying guidance might include:
For sexual wellbeing, this leaves room for more than one valid starting point. Someone distressed by reduced desire deserves to have that concern taken seriously. Someone whose main concern is mood or daily functioning should not have to make libido the centre of the discussion to explain that menopause is affecting them.
This is consistent with considering sexual changes within the wider context of midlife health and priorities. It does not require treating every change as a problem. It requires enough space to understand which changes matter to the individual.
The most useful part of Fallows's message is this shift in emphasis. Menopause care can acknowledge sexual desire while also asking what else has changed and what the person hopes support will address.
A woman's account of her own life may be less tidy than a symptom list. That is precisely why it deserves room in the conversation.
Being able to name the concerns behind a change in desire is a useful outcome of menopause education. Sexential addresses the difficulty of sorting hormonal influences from physical, psychological and relationship factors through clear explanations for adults aged 35 to 65. Its focus is understanding sexual wellbeing as life changes, not diagnosing readers or directing their treatment.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
Microplastics appeared in all 48 samples in an infertility study. A clear look at the semen findings, their limits and current fertility guidance.
A review of new advice on sexual pleasure after 40, with context on changing preferences, mutual choice and symptoms that need medical attention.
Understand menopause-related vaginal comfort, changing desire, practical comfort options and when to seek individualized medical advice.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
